Research Article
PARP1-Driven Apoptosis in Chronic Lymphocytic Leukemia
Table 1
Patient characteristics: epidemiology, disease characteristics, treatment, and response.
| | Characteristic | All patients | Subset of patients that received treatment |
| | Number of patients, (%) | 26 (100) | 15 (100) | | Median age, years (range) | 74 (51–87) | 73 (51–82) | | Male to female ratio | 1.5 | 1.4 | | Peripheral blood lymphocytes, ×109/L (range) | 29.4 (3.9–81.0) | 26.7 (3.9–81.0) | | LDH/ULN at presentation, mean (range) | 1.2 (0.9–3.1) | 1.1 (0.9–2.7) | | Previous treatment, (%) | 2 (7.7) | 2 (13.3) | | Disease stage (Binet) (15.24), (%) | | | | A | 10 (38.5) | 0 (0) | | B | 9 (34.6) | 8 (53.3) | | C | 7 (26.9) | 7 (46.7) | | Immunochemotherapeutic regimen, (%) | NA | | | R | | 8 (53.3) | | R, Ch | | 3 (20.0) | | FCR | | 4 (26.7) | | Response to treatment, (%) | NA | | | Complete response | | 3 (20.0) | | Partial response | | 10 (66.7) | | Stable disease | | 2 (13.3) | | Disease progression | | 0 (0) |
|
|
ULN: upper limit of normal; R: rituximab; Ch: chlorambucil; F: fludarabine; C: cyclophosphamide.
|
